Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women.

Zhu B, Nestorov I, Zhao G, Meka V, Leahy M, Kam J, Sheikh SI.

Clin Pharmacol Drug Dev. 2017 Nov;6(6):604-613. doi: 10.1002/cpdd.377. Epub 2017 Aug 7.

2.

The pharmacokinetics of 12-week continuous contraceptive patch use.

Lavelanet AF, Rybin D, White KO.

Contraception. 2017 Jun;95(6):578-585. doi: 10.1016/j.contraception.2017.03.002. Epub 2017 Mar 8.

PMID:
28285154
3.

Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery system.

Sriprasert I, Stanczyk FZ, Archer DF.

Expert Opin Pharmacother. 2015;16(12):1901-9. doi: 10.1517/14656566.2015.1056733.

PMID:
26194214
4.

Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol.

Song IH, Borland J, Chen S, Wajima T, Peppercorn AF, Piscitelli SC.

Ann Pharmacother. 2015 Jul;49(7):784-9. doi: 10.1177/1060028015580637. Epub 2015 Apr 10.

5.

Transdermal contraception methods: today's patches and new options on the horizon.

Nelson AL.

Expert Opin Pharmacother. 2015 Apr;16(6):863-73. doi: 10.1517/14656566.2015.1022531. Review.

PMID:
25800084
6.

A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.

Gruber D, Skřivánek A, Serrani M, Lanius V, Merz M.

Contraception. 2015 Feb;91(2):105-12. doi: 10.1016/j.contraception.2014.10.003. Epub 2014 Oct 13.

PMID:
25453582
7.

Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.

Hofmann B, Reinecke I, Schuett B, Merz M, Zurth C.

Int J Clin Pharmacol Ther. 2014 Dec;52(12):1059-70. doi: 10.5414/CP202064.

8.

Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.

German P, Moorehead L, Pang P, Vimal M, Mathias A.

J Clin Pharmacol. 2014 Nov;54(11):1290-8. doi: 10.1002/jcph.346. Epub 2014 Jun 24.

PMID:
24925712
9.

Metabolic effects of the contraceptive skin patch and subdermal contraceptive implant in Mexican women: a prospective study.

Hernandez-Juarez J, Garcia-Latorre EA, Moreno-Hernandez M, Moran-Perez JF, Rodriguez-Escobedo MA, Cogque-Hernandez G, Julián-Nacer R, Hernandez-Giron X, Palafox-Gomez R, Isordia-Salas I, Majluf-Cruz A.

Reprod Health. 2014 Apr 26;11:33. doi: 10.1186/1742-4755-11-33.

10.

Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.

Bifano M, Sevinsky H, Hwang C, Kandoussi H, Jiang H, Grasela D, Bertz R.

Antivir Ther. 2014;19(5):511-9. doi: 10.3851/IMP2718. Epub 2013 Dec 17.

PMID:
24343001
11.

Antimüllerian hormone levels decrease in women using combined contraception independently of administration route.

Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T, Tapanainen JS.

Fertil Steril. 2013 Apr;99(5):1305-10. doi: 10.1016/j.fertnstert.2012.11.034. Epub 2012 Dec 20.

PMID:
23260855
12.

Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users.

Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, Sorel M, Quesenberry CP Jr, Cooper WO.

Contraception. 2013 Jan;87(1):93-100. doi: 10.1016/j.contraception.2012.09.015. Epub 2012 Oct 19.

PMID:
23083525
13.

Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.

Upreti VV, Hsiang CB, Li L, Xu X, LaCreta FP, Boulton DW.

Diabetes Obes Metab. 2012 Dec;14(12):1155-7. doi: 10.1111/j.1463-1326.2012.01635.x. Epub 2012 Jul 9.

PMID:
22776778
14.

Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective.

Raymond EG, Burke AE, Espey E.

Obstet Gynecol. 2012 May;119(5):1039-44. doi: 10.1097/AOG.0b013e31825194ca.

PMID:
22525916
15.

Allergic contact dermatitis caused by an ethinylestradiol-norelgestromin transdermal therapeutic system.

Alfaya T, Mur Gimeno P, Iglesias AM, Ventura P.

Contact Dermatitis. 2011 Apr;64(4):242-4. doi: 10.1111/j.1600-0536.2011.01880.x. No abstract available.

PMID:
21392036
16.

High levels of women's satisfaction and compliance with transdermal contraception: results from a European multinational, 6-month study.

Jakimiuk AJ, Crosignani PG, Chernev T, Prilepskaya V, Bergmans P, Von Poncet M, Marelli S, Lee EJ.

Gynecol Endocrinol. 2011 Oct;27(10):849-56. doi: 10.3109/09513590.2010.538095. Epub 2010 Dec 10.

17.

[Combined hormonal contraception in cycles artificially extended].

Bustillos-Alamilla E, Zepeda-Zaragoza J, Hernández-Ruiz MA, Briones-Landa CH.

Ginecol Obstet Mex. 2010 Jan;78(1):37-45. Spanish.

PMID:
20931801
18.

Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.

Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, Cohn SE.

J Acquir Immune Defic Syndr. 2010 Dec;55(4):473-82. doi: 10.1097/QAI.0b013e3181eb5ff5.

19.

Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study.

Massaro M, Di Carlo C, Gargano V, Formisano C, Bifulco G, Nappi C.

Contraception. 2010 Mar;81(3):209-14. doi: 10.1016/j.contraception.2009.09.011. Epub 2009 Oct 29.

PMID:
20159176
20.

Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.

Schwartz JI, Liu F, Wang YH, Pramanik B, Johnson-Levonas AO, Gutierrez MJ, Lai E, Wagner JA.

Am J Ther. 2009 Nov-Dec;16(6):487-95. doi: 10.1097/MJT.0b013e3181985130.

PMID:
19940609

Supplemental Content

Loading ...
Support Center